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Oxidative stress appears to be a key feature of many neurodegenerative diseases either
as a cause or consequence of disease. A range of molecules are subject to oxidation,
but in particular, proteins are an important target and measure of oxidative stress.
Proteins are subject to a range of oxidative modifications at reactive cysteine residues,
and depending on the level of oxidative stress, these modifications may be reversible or
irreversible. A range of experimental approaches has been developed to characterize
cysteine oxidation of proteins. In particular, mass spectrometry-based proteomic
methods have emerged as a powerful means to identify and quantify cysteine oxidation
sites on a proteome scale; however, their application to study neurodegenerative
diseases is limited to date. Here we provide a guide to these approaches and
highlight the under-exploited utility of these methods to measure oxidative stress
in neurodegenerative diseases for biomarker discovery, target engagement and to
understand disease mechanisms.
Keywords: oxidation, oxidative stress, proteomics, neurodegenerative disease, amyotrophic lateral sclerosis
(ALS), Alzheimer’s disease
INTRODUCTION
Post-translational modifications (PTMs) of cysteine (Cys) residues play a crucial role in protein
function and cellular homeostasis. In particular, cysteine residues are sensitive to oxidative stress
and are subject to a range of reversible and irreversible oxidations. Many mass spectrometry (MS)-
based proteomics approaches have been developed to identify and measure levels of oxidized
cysteine residues (Oxi-Cys) in a range of biological systems. These quantitative proteomics
approaches include the analysis of reversible, irreversible and specific sub-types of Oxi-Cys PTMs.
Oxidative stress is a pathological feature of a range of neurodegenerative diseases, but proteomics
methods to study Oxi-Cys PTMs in this context are underexploited. In this review, we survey
state-of-the-art approaches for Oxi-Cys PTMs analysis to guide researchers who wish to exploit
proteomics to probe cysteine oxidation in neurodegenerative disease.
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Cysteine Oxidation
Among four common sulfur-containing amino acids,
homocysteine, taurine, methionine and cysteine, only the
latter two are incorporated into proteins. Although both of these
two play essential roles in cell metabolism, cysteine plays a crucial
role in the structure of proteins and protein-folding pathways
because of its ability to form intra- (inside a protein) and inter-
chain (different proteins) linkages with other cysteine residues
(Brosnan and Brosnan, 2006). Only 2.3% of the human proteome
encodes Cys residues, but their activities vary depending on their
states, mainly reduced or oxidized forms, within proteins. Many
attempts have been performed to characterize oxidation states of
specific Cys residues, but success has been limited because of the
low abundance of oxidatively modified Cys in biological systems
and the diversity of its oxidative products. The oxidation of other
amino acids also plays an important role in neurodegenerative
diseases (such as methionine and tyrosine oxidation) (Shi and
Carroll, 2020), but they are not the focus of this review.
There are two primary levels of Oxi-Cys residues in proteins
depending on the level of cellular oxidative stress, reversible
and irreversible Cys oxidations. The reversible oxidation of
Cys, such as S-nitrosylation (S-NO), S-sulfenylation (S-OH),
S-glutathionylation (S-SG), and disulphide formation (S–S)
Abbreviations: 2-D gel, two-dimensional gel; 2-ME, 2-mercaptoethanol; AD,
Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; Aβ, amyloid-beta; Biotin–
HPDP, N-[6-(biotinamido) hexyl]-3′-(2′-pyridyldithio) propionamide; BME,
β-mercaptoethanol; BST, biotin switch technique; CAM, carbamidomethyl group;
CBK, photocaged bromomethyl ketone; CIK4, iodomethyl; CNS, central nervous
system; CSF, cerebrospinal fluid; Ctrl, control; CuAAC, copper(I)-catalyzed
azide–alkyne cycloaddition; Cys, cysteine; CysTMT, cysteine-reactive tandem
mass tag; CysTMTRAQ, cysteine-reactive tandem mass tag and isobaric tags
for relative and absolute quantitation; DDA, data-dependent acquisition; DIA,
data-independent acquisition; DTBA, dithiobutylamine; DTT, dithiothreitol;
EBX, ethynyl benziodoxolone; ELISA, enzyme-linked immunosorbent assay;
ERW3, fluoronitrobenzene; ESI, electrospray ionization; FFI, fatal familial
insomnia; FTD, frontotemporal dementia; HC, healthy control; HPDP, N-
[6-(biotinamido) hexyl]-3′-(2′-pyridyldithio) propionamide (biotin–HPDP);
HRMS1, high resolution MS1; IA, immunoaffinity; IAA, iodoacetic acid; IAM,
iodoacetamide; iCAT, isotope-coded affinity tag; iodoTMT, iodoacetyl isobaric
tandem mass tags; IPL, inferior parietal lobule; isoTOP-ABPP, isotopic tandem
orthogonal proteolysis-activity-based protein profiling; iTRAQ, isobaric tags
for relative and absolute quantitation; LFQ, label free quantification; MCI, mild
cognitive impairment; MMTS, methanethiosulfonate; MND, motor neuron
disease; MnSOD, manganese superoxide dismutase; MRM, multiple reaction
monitoring; MS, mass spectrometry; MS, multiple sclerosis; MTRP, multiplexed
thiol reactivity profiling; NaAsc, sodium ascorbate; ND, neurodegenerative
diseases; NEM, N-ethylmaleimide; NLRP3, NOD-like receptor family, pyrin
domain containing 3; NMDA, N-methyl-D-aspartate; NOD, nucleotide-binding
and oligomerization domain; NPH, normal pressure hydrocephalus; NPM,
N-propargylmaleimide; OxcyscPILOT, oxidized cysteine-selective combined
precursor isotopic labeling and isobaric tagging; Oxi-Cys, oxidative cysteine;
PD, Parkinson’s disease; PRM, parallel reaction monitoring; p-SRM, pseudo-
selected reaction monitoring; PTM, post-translational modification; RAC,
resin-assisted capture; RB2, chloropyridine; ROS, reactive oxygen species; sCJD,
Creutzfeldt–Jakob disease; SDS–PAGE, sodium dodecyl sulfate –polyacrylamide-
gel electrophoresis; SH, sulfhydryl; SILAC, stable isotope labeling by amino
acids in cell culture; S-NO, S-nitrosylation; SNOTRAP, S-NO trapping by triaryl
phosphine; S-O2H, S-sulfinylation; S-O3H, S-sulfonylation; SOD1, superoxide
dismutase type-1; S-OH, S-sulfenylation; SPS, synchronous precursor selection;
SRM, selected reaction monitoring; S-SG, S-glutathionylation; SWATH-MS,
sequential window acquisition of all theoretical mass spectra; TCA, trichloroacetic
acid; TCEP, Tris(2-carboxyethyl)phosphine; TEV, tobacco etch virus; TMT,
isobaric tandem mass tags; TOF, time-of-flight; TOP, tandem orthogonal
proteolysis; TTP, transthyretin; UPLC, ultra performance liquid chromatography;
XIC, extracted ion chromatogram.
(Figure 1), is found under low oxidative conditions and acts to
modulate protein function (Dalle-Donne et al., 2005). However,
at higher levels of oxidative stress, the oxidative state of Cys
is elevated and harder to reverse (S-sulfinylation, S-O2H) or
becomes irreversible (S-sulfonylation, S-O3H, or S-sulfinylation)
(Figure 1), causing the loss of protein function (Murray and
Eyk, 2012). The determination of dynamic changes in site-specific
Cys oxidation will provide vital information to understand the
distribution of redox balance states in neurodegenerative diseases
and to characterize dysregulated oxidation in patients compared
to healthy control (HC) groups. The reversible oxidation states
of Cys may also reflect the fluctuations of cellular oxidation
status, and both reversible and irreversible oxidation status of Cys
may serve as biomarkers of neurodegenerative diseases associated
with oxidative stress.
Oxidative Stress in Neurodegeneration
Multiple lines of evidence point to a role for elevated oxidative
stress in driving neuronal degeneration in neurodegenerative
diseases such as Alzheimer’s disease (AD) (Markesbery and
Carney, 1999), Parkinson’s disease (PD) (Puspita et al., 2017)
and amyotrophic lateral sclerosis (ALS) (Barber and Shaw,
2010). We are still unsure whether oxidative stress is a cause
or consequence of neuronal degeneration. In addition, many
therapeutic approaches have been tested in clinical studies in
an attempt to limit pro-oxidative mediated neuronal injury.
However, few of these approaches, except Edaravone for ALS
(Group, 2017), have been successful.
Oxidative stress has broadly been considered an imbalance
in pro and anti-oxidant processes, leading to elevated pro-
oxidant activity in cells, leading to cellular injury and death
(Guo et al., 2013; Song et al., 2021). For example, a common
denominator in neurodegenerative diseases is the presence of
oxidatively damaged macromolecules in neurons and glia and
other biosamples. However, oxidative stress is probably better
understood as a disruption of the interplay between different
inter-related cellular redox systems and their control (Jones,
2006). Therefore, to understand and therapeutically modulate
redox control and signaling in neurodegeneration, it is critical
to measure the status of these different redox systems. Cysteine
redox cycling is a key component of these systems, and the study
of this pathway has been relatively neglected to date. However,
it is eminently accessible via proteomic approaches, enabling a
global view of cysteine redox regulation.
The refinement of measures of complex redox biology in the
central nervous system (CNS) directly in patients, as disease
progresses, would greatly facilitate both the understanding of
the role that redox regulation plays in neurodegeneration,
but importantly would also enable identification of novel
biomarkers for evaluating therapeutic interventions targeted at
oxidative stress. So-called target engagement biomarkers are
considered critical in the development of novel therapeutics
(Durham and Blanco, 2015).
The misfolding and aggregation of amyloid-beta (Aβ) and
tau in AD and superoxide dismutase type-1 (SOD1) in ALS
results in a progressive loss of specific populations of neurons
that is strongly associated with mitochondrial dysfunction,
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FIGURE 1 | Different types of Oxy-Cys PTMs occurring in proteins.
neuroinflammation and excitotoxicity (Andersen, 2004; Guo
et al., 2013; Song et al., 2021). These pathological processes lead
to increased generation of free radicals, redox imbalance which
further impairs cellular function, leading to neuronal cell death.
Protein aggregates are formed by oxidatively altered proteins
that misfold and accumulate. Multiple PTMs may contribute
to protein misfolding; one of these is Cys oxidation (Olzscha,
2019). Several mutations in the Cu/Zn superoxide dismutase
gene (SOD1) cause familial amyotrophic lateral sclerosis (FALS).
There is also evidence to suggest that oxidized wild-type SOD1
adopts a conformation similar to mutant SOD1, which could be
pathogenic in sporadic ALS (Bosco et al., 2010). In another study,
the oxidation of C111 on SOD1 via glutathionylation (S-SG) was
found to decrease the stabilization of SOD1 dimer, increasing
the potential for the unfolding of the monomer and subsequent
aggregation and, as a result, leads to loss of SOD1 activity and
promotion of cell death (Redler et al., 2011). Peroxiredoxins
(Prxs), enzymes that neutralize reactive oxygen/nitrogen species,
have been implicated in several neurodegenerative diseases,
including AD and PD. They act to reduce peroxynitrite and
other hydroperoxides through a redox-sensitive Cys within their
active sites; they reduce peroxide substrates via the formation
of intramolecular disulphide bonds or oxidation to sulfinic acid
or sulfonic acid (Hall et al., 2009). The protective function of
PRDX2, the most abundant peroxiredoxin in neurons, against
oxidative stress is inhibited by oxidation of the enzyme itself.
S-NO of PRDX2 at the active-site residues Cys 51 and 172 inhibits
the enzyme activity, the level of which is increased in human PD
brains (Fang et al., 2007).
In AD, S-NO can have both neuroprotective and neurotoxic
functions (Zhao et al., 2015). For example, S-NO of
the N-methyl-D-aspartate (NMDA) receptor inhibits its
overactivation and promotes neuronal survival (Nakamura and
Lipton, 2007). In contrast, many proteins that are key to normal
synaptic function are aberrantly S-nitrosylated in AD, which
results in synaptic damage and neurodegeneration (Nakamura
et al., 2013). Therefore, targeting protein S-NO can prove useful
as a new therapeutic intervention for AD neurodegeneration.
Neurons are particularly susceptible to oxidative stress
because of the high energy demand, which depends heavily on
robust mitochondrial function. Under physiological conditions,
mitochondria serve as a primary source of reactive oxygen
species (ROS) in the cell and in normal conditions, the
physiological antioxidant defense systems can neutralize these.
However, mitochondrial dysfunction leads to increased ROS
levels and has been implicated in AD pathology (Lin and Beal,
2006). Swerdlow and Khan (2004) and Swerdlow et al. (2014)
proposed a ‘mitochondrial cascade hypothesis,’ which suggests
that oxidative stress and amplified generation of ROS trigger Aβ
aggregation and neurodegeneration. In vitro models of both AD
and ALS provided evidence that mitochondrial fragmentation
and dysfunction trigger ROS production by microglia, resulting
in neuronal damage (Joshi et al., 2019). In a mouse model
of AD, partial deficiency of manganese superoxide dismutase
(MnSOD) is known to induce oxidative stress, elevated Aβ levels
and plaque deposition (Li et al., 2004). In another AD mouse
model, pharmacological inhibition of energy production was also
amyloidogenic, and metabolic dysregulation has been suggested
to be an early pathological event in AD (Velliquette et al.,
2005). These results support the hypothesis that altered energy
metabolism is a key mechanism in AD.
Studies on neuroinflammation have generated more evidence
showing the role of ROS in AD. For example, activation
of the NOD-like receptor family, pyrin domain containing 3
(NLRP3) inflammasome, has been widely implicated in various
neurological disorders (Shao et al., 2018). One of the main
features of AD is microglial activation, which enhances the
release of pro-inflammatory molecules, including ROS, and
contributes to the propagation of the disease. Aβ promotes
the accumulation of mitochondrial ROS, which causes NLRP3
inflammasome activation (Wang et al., 2017). The activation of
the NLRP3 inflammasome is thought to seed and spread the Aβ
pathology within and between brain structures (Venegas et al.,
2017). Moreover, there is strong evidence suggesting that NLRP3
inflammasome activation by ROS also drives tau pathology
(Ising et al., 2019). Therefore, this example shows a clear
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FIGURE 2 | An overview of Oxi-Cys quantitative proteomics approaches for different types of Cys oxidations. Chemicals used for selective Oxi-Cys proteomics
analysis. Free reduced Cys residues are firstly labeled with alkylating reagents (IAM, NEM, MMTS, etc.) while different PTMs of reversible Oxi-Cys residues are
selectively alkylated by specific reducing regents; for example, DTT/TCEP for reducing all reversible Cys, arsenite for S-sulfenylation (S-OH), ascorbate for
S-nitrosylation (S-NO), glutaredoxin for S-glutathionylation (S-SG). These newly formed reduced Cys residues then, theoretically, can be labeled by different alkylating
reagents or specific probes coupled with tags for purification/enrichment. The quantitation is performed based on comparing intensities of tags from diseased
compared to control groups. S-OH probes include: dimedone and bicyclononyne BCN; S-O2H probes include: C-nitroso esters, diazenes and S-nitrosothiols as
detailed in Figures 5A,B.
connection between neuroinflammation and ROS production
occurring in Aβ- and tau-related neurodegeneration. Since
oxidative damage is associated with both healthy aging and
disease, understanding the mechanisms of cellular oxidation
status in aging and neurodegeneration may lead to new strategies
for their prevention.
Overview of Oxi-Cys Proteomics
In the field of Oxi-Cys proteomics, one of the main challenges
lies in the sample preparation methods used to access (and
preserve) the initial oxidation state of proteins within oxidative
environments. A general protocol for MS-based Oxi-Cys
proteomics includes two main steps: chemical labeling reduced
and oxidized cysteine residues and MS-based analysis to identify
and quantify peptides (bottom-up) or intact proteins (top-
down) containing labeled cysteine residues. The key steps for
sample preparation and labeling of cysteine-containing proteins
consist of extracting proteins using appropriate buffers, blocking
free reduced cysteine residues, reducing reversibly oxidized
cysteines using either reducing reagents or targeting the type
of oxidation of interest using suitable probes. Subsequently,
labeled and/or purified proteins/peptides are analyzed by MS.
For the bottom-up proteomics approach, labeled proteins are
enzymatically digested into peptides (typically using trypsin)
to generate a complex mixture of peptides, which is then
analyzed directly by MS analysis or fractionated using HPLC
to reduce the complexity of peptide mixture before MS
analysis of each fraction. For top-down analysis, an intact
protein is enriched/purified using suitable techniques before
being directly analyzed and fragmented in a tandem mass
spectrometer (Virág et al., 2020). As the intact protein is
analyzed, the context of multiple PTMs and protein isoforms
is retained (Tran et al., 2011), unlike bottom-up proteomics,
where the connection between PTMs on different peptides is
lost. However, sequence coverage is generally much lower in top-
down versus bottom-up proteomics. Top-down proteomics is
not currently well suited for the analysis of complex mixtures
of proteins (Lorenzatto et al., 2015), and data analysis can
be complex and time-consuming. As a result, this approach
is not currently routinely used for high-throughput proteomic
analysis, and only a few studies have used this approach to
study protein oxidation (Tran et al., 2011; Ansong et al.,
2013; Auclair et al., 2014; Reinwarth et al., 2014). Therefore,
in this review, we will highlight the most currently used




There are many considerations for the experimental design
for proteomic analysis of Oxi-Cys PTMs. These include the
types of Cys-oxidations of interest, number of biological
samples, selection of approaches (reactive thiols or oxidized
Cys), incorporation of chemical tags, enrichment method,
availability of antibodies, and type of quantitation (Gu and
Robinson, 2016b). In Oxi-Cys based analysis, abundance changes
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TABLE 1 | Advantages and disadvantages of current Oxi-Cys
proteomic approaches.
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TABLE 1 | Continued
























































































in peptides containing oxidized Cys will directly reflect the
oxidation level in a given sample/experiment. In thiol reactivity
profiling experiments, abundance changes in reduced Cys will
reflect the oxidative level of Cys inversely. Generally, a typical
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workflow for Oxi-Cys proteomics analysis in neurodegenerative
diseases should cover:
• Types of Oxi-Cys PTMs of interest (global or selected
PTMs as seen in Figure 1) to ensure that, in the case
of selected Oxi-Cys, the (affinity) purification method is
available and suitable.
• Quantitative approaches to be used, as this will determine
the types of thiol alkylations, appropriate reagents,
protein/peptide enrichment and labeling, MS [MS/MS(n)]
operation, and cost-effectiveness.
• Type of MS instrument available for sample analysis.
These key factors will affect the selection of appropriate
approaches, MS (MS/MS) mode operation, and downstream data
processing.We have summarized themain proteomic approaches
for different types of Oxi-Cys PTM analyses in Figure 2, and their
applications, advantages and disadvantages are shown in Table 1
and Supplementary Table 1, respectively. The details of these
approaches are discussed in the following sections.
There are two main types of Oxi-Cys analysis: global Oxi-Cys
and selective Oxi-Cys measurement (Figure 2). Traditionally,
for any relative quantitative analysis of Oxi-Cys, at least two
different biological groups are required. The global quantitative
Oxi-Cys analysis can be performed based on the ratio of Cys-
containing peptide XIC (extracted ion chromatogram) intensities
detected by MS (either reduced or oxidized Cys intensities)
between samples. This type of analysis includes two different
alkylating steps (e.g., IAM and NEM), stable isotopic labeling
(SICyLIA), resin-assisted capture (RAC) combined with isobaric
labeling reagents (TMT, iTRAQ, and iCAT). Irreversible cysteine
oxidations are typically stable during sample processing and LC-
MS conditions; thus, direct analysis of these modifications in a
complex sample is feasible.
Differential Alkylation
Chemically Distinct Alkylation Reagents
One of the biggest challenges of reversible Oxi-Cys analysis
is to preserve the endogenous redox state. This can be
affected by either oxidation or reduction of Cys during
sample preparation leading to inaccurate cellular redox balance
measurement. To minimize the artefactual oxidation, alkylating
reagents such as Iodoacetamide (IAM) or N-ethylmaleimide
(NEM) are added at the first step during protein denaturation
to alkylate reduced Cys residues (McDonagh et al., 2014).
This is a crucial step for relative quantification, and it is
required that the alkylating reagent should completely block
all reduced Cys. Subsequently, all reversible Oxi-Cys residues
are reduced by reducing agents, such as dithiothreitol (DTT),
dithiobutylamine (DTBA), β-mercaptoethanol (BME), or tris(2-
carboxyethyl)phosphine (TCEP) to generate free sulfhydryl
groups. This is followed by the second alkylation step, where
newly formed sulfhydryl groups are chemically blocked with
an alkylating reagent distinct from that used in the first step
[e.g., NEM, IAM, 2-chloroacetamide, iodoacetic acid (IAA),
4-vinylpyridine, methanethiosulfonate (MMTS)] (McDonagh
et al., 2014). Proteins are then enzymatically digested, and
the generated peptides can then be fractionated, if necessary,
via an off-line HPLC and fractions analyzed by LC-MS/MS
(Figure 3A). Intensities of reduced Cys and Oxi-Cys-containing
peptides from samples are compared to estimate the ratio
of Oxi-Cys. This approach is relatively straightforward, and
from the same analysis, protein expression measurement can
be performed using label-free quantification of non-cysteine
containing peptides. However, given that this approach does
not include a cysteine enrichment step, the coverage of Cys-
containing peptides for complex samples may be lower than
that achievable using other methods that do incorporate an
enrichment step.
Stable Isotopic Labeling With Iodoacetamide
(SICyLIA)
An approach using stable isotope cysteine labeling with IAM,
termed SICyLIA, has been recently developed to investigate
global Oxi-Cys proteomes (van der Reest et al., 2018). This
approach utilizes light or heavy isotope-labeled IAM to differently
label reduced Cys thiols between two groups (e.g., control and
experimental). A detailed workflow of this approach is shown
in Figure 3B. During denaturing, free reduced Cys residues
in control and experimental samples are alkylated using either
light (12C2H4INO) or heavy (
13C2D2H2INO) IAM, respectively
which results in the addition of a carbamidomethyl group
(CAM), adding an extra of 57 or 61 Da to cysteine residues
(Figure 4A); or free reduced Cys can be also alkylated with
either light or heavy NEM (Figure 4B). These two samples are
then combined and reduced using DTT; newly reduced Cys
generated from reversible Oxi-Cys are alkylated with NEM and
subjected to tryptic digestion to generate labeled peptides. The
mixture of these peptides is then fractionated off-line by a high
pH reversed-phase chromatography to reduce the complexity
of the peptide mixture to increase proteome coverage. Peptide
fractions of labeled peptides are then analyzed by LC-MS/MS.
The ratio (of signal intensity) between heavy and light IAM-
labeled Cys-containing peptides will estimate reduced cysteine
levels between two samples with an assumption that any decrease
in CAM-modified peptides will reflect an increase in the level
of oxidation (van der Reest et al., 2018). Given that the reduced
Cys portion of proteins is more abundant in cells, this approach
does not require an enrichment step and allows enhanced
detection of oxidation changes in cells (van der Reest et al.,
2018). However, this approach cannot distinguish specific forms
of reversible Oxi-Cys, as all reversible Oxi-Cys residues are
labeled and analyzed.
Isobaric Tags
Iodoacetyl Isobaric Tandem Mass Tags – IodoTMT
Iodoacetyl isobaric tandem mass tags (iodoTMT) allows the
pooling and analysis of up to six samples in a single Oxi-
proteomics experiment. The iodoTMTsixplex reagents consist of
six different isobaric isomers that can react with the sulfhydryl
(-SH) group of protein via irreversible labeling step by forming
an iodoacetyl-activated covalent bond (Bomgarden et al., 2012).
The workflow of this approach is presented in Figure 3C,
and the chemical structures of iodoTMTsixplex reagents with
Frontiers in Molecular Neuroscience | www.frontiersin.org 6 June 2021 | Volume 14 | Article 678837
Pham et al. Neuroproteomics of Cysteine Oxidation
FIGURE 3 | Non-click chemistry-based thiol-reactive workflows. Different alkylation methods: (A) two chemically distinct alkylation reagents and (B) SICyLIA;
isobariac tags: (C) iodoTMT and (D) cysTMTTRAQ.
the distribution of isotopes and their reaction with reduced
Cys are shown in Figure 4C. Each iodoTMT reagent contains
three distinctive groups (Figure 4C), including a reporter (used
for quantitation), mass normaliser (balance group) and a Cys
reactive group (to react with a sulfhydryl group) (Bomgarden
et al., 2012). Different iodoTMT reagents can be used to label
either reduced or oxidized Cys residues (reduced before labeling)
depending on the design of the experiment. The ion reporters
(isobaric mass tags) are cleaved during MS2 (fragmentation)
analysis generating unique reporter ions ranging from 126 – 131
m/z (Figure 4C). Their intensities in fragmentation spectra are
then used to calculate the level of Cys oxidation from the samples
(Bomgarden et al., 2012).
This approach can be used for either global Cys (reduced
and reversible oxidized forms) or Oxi-Cys analyses. If it is
used for global Cys analysis, all proteins are denatured and
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FIGURE 4 | Isotope labeled reagents and probes used for Oxi-Cys proteomics. Isotopic chemicals and their adding extra mass for PTM search: (A) L-IAM and
H-IAM, (B) L-NEM, and H-NEM, (C) iodoTMT reagents and the cleavage site to release ion reporters by CID during MS/MS analysis.
reduced with TCEP to ensure that all reversible Oxi-Cys are
reduced. All initially and newly reduced Cys-containing proteins
in each sample are then labeled with appropriate iodoTMT
reagent; up to six samples can be labeled with six specific
iodoTMT reagents (Figure 3C). If an iodoTMT approach
is used for analyzing reversible Oxi-Cys, proteins are firstly
denatured in the presence of IAM to block reduced Cys;
the excess IAM is removed via trichloroacetic acid (TCA)
precipitation of proteins. Subsequently, proteins are reduced
with DTT to covert reversible Oxi-Cys to free thiols that
are then labeled with iodoTMT reagents. All labeled proteins
are pooled and precipitated by TCA to remove the excess
iodoTMT reagents, followed by tryptic digestion (Bomgarden
et al., 2012). Labeled iodoTMT peptides are enriched using
immobilized anti-TMT antibody resin and eluates analyzed by
LC-MS/MS. The intensity of ion reporters generated during
MS2 analysis will be used for relative quantitation of Oxi-
Cys while other MS2 information is used for peptide/protein
sequencing.
This iodoTMT approach can also be used for selective Oxi-
Cys analysis. Qu et al. (2014) combined biotin switch technique
(BST) [adopted from (Jaffrey et al., 2001), see section Biotin
Switch Technique (BST) for details] with iodoTMT labeling to
improve the iodoTMT approach, such as robust workflow for
S-NO PTM analysis, effective peptide digestion, unambiguous
S-NO-Cys mapping, and enhanced high throughput (Qu et al.,
2014). In brief, Cys residues containing free thiols are alkylated
with MMTS, while nitrosylated Cys residues are selectively
reduced with ascorbate and labeled with iodoTMT reagents. Six
different iodoTMT labeled samples are then combined, reduced
(by DTT) and alkylated (by IAM), digested by trypsin. Labeled
peptides are enriched by anti-TMT antibody resin before being
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analyzed by LC-MS/MS. The enrichment efficiency of iodoTMT
labeled peptides is low but optimization of elution conditions
has increased the efficiency from 6% using standard conditions
to 21% (Qu et al., 2014). In theory, iodoTMT can be used
for the investigation of most common reversible Oxi-Cys by
a combination of selected methods for enrichment of different
kinds of Oxi-Cys (as shown in Figure 2) and iodoTMT for
labeling of interested Oxi-Cys PTM.
Cysteine-Reactive Tandem Mass Tag (cysTMT) and
Isobaric Tags for Relative and Absolute Quantitation
(iTRAQ) – cysTMTRAQ
Conventional multiplexing approaches such as iodoTMT, which
provide a readout of the changes in thiol redox state,
do not allow measurement of global changes in protein
expression. To overcome this, the double-labeling approach
termed cysTMTRAQ combining two different isobaric tag
approaches, the cysTMT and iTRAQ, was developed (Parker
et al., 2015). The cysTMT approach utilizes two different isobaric
tag groups with two different purposes: the cysTMT tags are
used to label thiol groups on Cys in up to six samples (126,
127, 128, 129, 130, and 131 m/z), while the iTRAQ tags are
used to label N-terminal and lysine residues of peptides in up
to six various samples (114, 115, 116, 117, 119, and 121 m/z).
This approach, therefore, allows the simultaneous measurement
of the changes in Cys oxidation (from cysTMT) and changes in
global protein expression (from iTRAQ). This allows cysteine
oxidation data to be normalized to protein expression data to
correct for changes in protein turnover (Parker et al., 2015). To
enhance the coverage of Oxy-Cys proteomes, the enrichment
of labeled proteins can be performed using a specific anti-TMT
antibody after two labeling steps, coupled with HPLC based
fractionation before MS analysis. The workflow of this approach
is shown in Figure 3D, and its benefits are shown in Table 2.
Although this approach offers many advantages, one of the main
problems is the ratio compression in quantitation caused by the
interference of both TMT and iTRAQ ion reporters; however, the
use of advanced modes of data acquisition such as synchronous
precursor selection (SPS) implemented in the current generation
of Orbitrap analyzers can solve this issue (Erickson et al., 2015).
Click Chemistry Approaches
Unlike SiCyLIA or iodoTMT, in which different isotopic labeling
reagents directly react with Cys residues in proteins without
any other further reactions, click chemistry-based approaches
(DiaAlk, TOP-ABPP) employ two reactions. Firstly, a probe
(containing specified alkyne and an IAM group) will react with
the thiol group in a protein (via IAM group) to form the
probe-protein intermediate. This is then biotinylated with isotope
labeled–biotin tags using a click chemistry reaction (via alkyne
group) to allow subsequent purification of tagged proteins using
avidin/streptavidin resins. Common probes used for selective
Oxy-Cys proteomics analysis and click chemistry approaches are
shown in Figure 5. Proteins labeled with either light or heavy
isotope tags are usually tryptically digested to generate labeled
peptides. Subsequently, the biotin group in these labeled peptides
will be cleaved off by either enzymes (isoTOP-BPP approach)
or UV (QTRP and DiaAlk approaches) at a specific wavelength,
allowing labeled peptides to be readily analyzed by LC-MS/MS
(see Figure 6). Based on signals of the (light and heavy) tag-
labeled peptides obtained at MS1 level, a ratio of light/heavy (or





IsoTOP-ABPP was developed as an advanced approach to
quantify/measure the reactivity of Cys residues directly in native
biological samples. It combines two different strategies; tandem
orthogonal proteolysis (TOP) and activity-based protein profiling
and has been used to predict functions of cysteine residues
in proteomes (Weerapana et al., 2007). This approach consists
of three main steps, alkylating reduced Cys in proteins with
a probe, click chemistry-based incorporation of isotopically-
labeled cleavable tags, protein purification and on-bead digestion
(Weerapana et al., 2007). A probe consists of two main
components: a reactive group to label reduced Cys residues
in proteins coupled with an alkyne group for tagging click
chemistry (Figure 4C). The TEV-biotin tag contains three
different components: a biotin group for streptavidin affinity
purification, a TEV (Tobacco etch virus) protease recognition
domain (ENLYFQG) conjugated to an isotopically labeled Valine
(heavy or light), and an azide handle for click chemistry, and
a linker between a reporter and the reactive group (Weerapana
et al., 2007; Chen et al., 2017) (Figure 7). The mass shift between
light and heavy version tags is 6.014 Da (Weerapana et al.,
2010).
A typical workflow of the isoTOP-ABPP approach employs
two different (light and heavy) isotopically labeled cleavable
biotin-azide tags that are reacted with IA-alkyne probes.
Copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) is used
to label two different experimental Cys-proteomes (Figure 6A).
Reactive cysteines in proteins from two distinct proteomes are
firstly alkylated with IA-alkyne probe, subsequently conjugated
with isotopically differentiated cleavable biotin-azide tag using
CuAAC (Kolb et al., 2001). IA-labeled proteins from two different
proteomes are combined and subjected to affinity purification
on streptavidin beads, followed by on-bead tryptic digestion.
All labeled cysteine-containing peptides are then released by
sodium dithionite before analysis by LC-MS/MS (Figure 6A).
The calculated heavy/light ratio of each labeled Cys peptide,
obtained from MS1 level analysis, will reflect Cys reactivity
changes between two proteomes.
Many attempts have been performed to improve the
performance of isoTOP-ABPP, mainly focused on cysteine
reactive electrophile probes, cleavable biotin-azide tags, and
heavy isotope incorporations (Maurais and Weerapana, 2019).
• Various probes recently introduced (summarized in
Figure 5C) include (i) IA-alkyne based probes such as
chloropyridine (RB2) and fluoronitrobenzene (ERW3)
(Shannon et al., 2014), a photocaged bromomethyl ketone
(CBK) (Abo and Weerapana, 2015), iodomethyl ketone
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FIGURE 5 | Structure of probes used for selective Oxi-Cys (A: S-OH and B: S-O2H) and click chemistry-based (C) approaches.
(CIK4), ethynyl benziodoxolone (EBX) (Abo et al., 2017),
and (ii) light and heavy isotopic IA-alkyne tags (Abo et al.,
2018), (iii) thiol-reactive probe (N-propargylmaleimide,
NPM) (McConnell et al., 2020).
• Different cleavable biotin-azide tags: protease-cleavable
biotin-azide tags for CuAAC-mediated conjugation
(TEV protease), chemically cleavable azobenzene (Azo)
linkers (Qian and Weerapana, 2017) (Figure 7), and
photocleavable biotin-azide tags such as reductive dimethyl
labeling (termed rdTOP-ABPP for triplex quantification)
(Yang et al., 2018) and multiplexed thiol reactivity
profiling (MTRP) (Tian et al., 2017), maleimide-activated
(Figure 8).
• Heavy isotope incorporation: for duplex analysis including
stable isotope labeling by amino acids in cell culture
(SILAC), isotopes of IA-alkyne tags (Abo et al., 2018)
(Figure 5C), light and heavy isotopic biotin-azide linkers
(Figure 7); for triplex analysis including reductive
dimethylation rdTOP-ABPP (Yang et al., 2018); and
multiplex including isobaric tags (iTRAQ, TMT).
The synthesis of isotope containing cleavable biotin tags [L-
Valine-N-Fmoc (13C5,
15N1)] is usually expensive and low yield,
but recently, a more cost-effective version of light and heavy
isotopes of IA-alkyne tags (Figure 5C) has been developed (Abo
et al., 2018). The availability of these three crucial developments
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FIGURE 6 | Click chemistry thiol-reactive workflows. (A) isoTOP-ABPP; (B) QTRP; (C) DiAlk. The Oxy-Cys quantitation of these approaches is based on MS1 level.
offers many combinations to tailor isoTOP-ABPP workflow to
suit specific experimental designs. Furthermore, when combined
with otherMS-based approaches (next Section), different variants
of isoTOP-ABPP can be customized to maximize Oxi-Cys
detection and quantitation.
Quantitative Thiol Reactivity Profiling (QTRP)
In a strategy similar to isoTOP-ABPP, a quantitative thiol
reactivity profiling (QTRP) approach was introduced for Oxi-
proteomics analysis in which IAM-alkyne probes are used
together with click chemistry for light and heavy isotope labeling
(Fu et al., 2017). This approach also uses an electrophilic
IAM-alkyne probe (2-iodo-N-(prop-2-yn-1-yl)acetamide, IPM,
Figure 5C) coupled with isotopically light (12C) and heavy (13C)
UV-cleavable azido-biotin tags via a click chemistry reaction
(CuAAC) (Figure 8). All free reduced Cys thiol groups are
firstly alkylated with IPM while reversible Cys are reduced
by DTT, alkylated with IAM and then digested into peptides
(Figure 6B). The peptides containing the IPM probe, from each
sample, are then conjugated with light or heavy UV-cleavable
azido-biotin tags (for control and compared samples) via copper
catalyzed alkyne azide cycloaddition reaction (CuAAC, click
chemistry) (Fu et al., 2017). Equal amounts of each sample
(light or heavy labeled peptides) are combined and purified
by streptavidin. Isotopically labeled peptides are then released
via a photorelease step (irradiated with 365 nm UV light)
(Fu et al., 2017). Mixed labeled peptides are then analyzed
by MS, and the light/heavy ratio of a given precursor peptide
derived from all isotopically labeled Cys peptides will indicate
the oxidation level of control against experimental samples. The
key difference between isoTOP-ABPP and QTRP is the order of
the labeling steps; while a chemistry click reaction is performed
at the protein level in isoTOP-ABPP approach, its reaction is
carried out at the peptide level in the QTRP approach, offering
a higher yield of biotinylated peptides (Fu et al., 2017), and
high selectivity. Recently an updated QTRP approach has been
introduced and enabled to detect 5,000 unique Cys-containing
peptides (Fu et al., 2020).
Electrophilic Diazene Probe (DiaAlk)
There is controversy regarding the biological functions of
S-sulfinylation and the extent of its reversibility. Furthermore,
the analysis of S-sulfinylation is challenged by other canonical
forms of Oxi-Cys, such as S-sulfhydration (-SSH). Indeed, a
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FIGURE 7 | Tags used in the isoTOP-ABPP workflow. Structure of light and heavy isotopic TEV-biotin tags used in isoTOP-ABP, their reaction with reduced Cys,
purification using streptavidin and release of labeled proteins using TEV protease.
mass difference of 32 Da between unmodified and S-sulfinylated
proteins in a standard proteomics workflow has been used
to detect S-sulfinic acid by MS (S-O2H). However, this type
of analysis has faced challenges, for example, the problem of
oxidation during sample preparation, the interference of other
PTMs with the same nominal mass shift [S-sulfhydration (-SSH),
for example] (Lee et al., 2013). To overcome these problems,
an alkyne derivative of di-t-butyl azodicarboxylate (DBAD)
(termed DiaAlk), coupled with isotopic tags, has been used
(Akter et al., 2018). The addition of the single alkyne tag to
convert DBAD into an asymmetrical molecule enables sulfinic
acid to be tagged at both positions of the N = N link in
DiaAlk (Akter et al., 2018) (Figure 8). Reduced Cys residues
in proteins (in both control and experimental samples) are
blocked with 4,4′-dipyridyldisulfide (4-DPS) to prevent thiol-
mediated probe consumption whilst sulfinylated Cys residues
are reacted with DiaAlk probe (Figure 6C). Subsequently, other
remaining types of Oxi-Cys residues are reduced (by DTT)
and alkylated (by IAM) to prevent the re-oxidation of newly
formed reduced Cys. Proteins are enzymatically digested (with
trypsin), and S-sulfinylated peptides are then conjugated to light
and heavy azide-biotin to form a photocleavable linker (Az-UV-
biotin) via Cu(I)-catalyzed azide-alkyne cycloaddition (Figure 8)
(for two distinct proteomes). Peptides from control and
experimental samples are combined before being purified using
streptavidin resin. Labeled-biotinylated peptides are released by
photocleavage of the biotin linker by irradiation under UV light
at 395 nm (Akter et al., 2018) and analyzed by LC-MS/MS.
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FIGURE 8 | Tags used in DiaAlk workflows. Structure of UV-biotin tags used in DiaAlk and their reaction with oxidized Cys (S-02H), purification using streptavidin,
and release of labeled proteins by UV light.
ENRICHMENT OF OXI-CYS PTMs
Given the content of Cys in proteins is low and oxidized Cys is
present at even lower levels, Cys enrichment is an important step
to increase the coverage of Oxi-Cys by MS. There are three main
methods to enrich Cys [details see Gu and Robinson (2016b)] as
listed below:
• Biotin switch technique (BST): ICAT, iTRAQ, SILAC.
• Thiol-affinity RAC: OxcysDML, OxcyscPILOT.
• Immunoaffinity purification: iodoTMT, light and heavy
isotopes NEM.
When Oxi-Cys quantitative analysis is performed across
multiple samples, it is required that the level of Cys oxidation
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FIGURE 9 | Considerations for choosing strategies for proteomic analysis of cysteine oxidation. Various features of each approach are included to help guide the
choice of methods. The shape (,©) and color code each represent a distinct method but are grouped according to the different overall approaches.
needs to be normalized to the level of protein expression,
usually requiring a separate experiment for global proteome
quantitation. However, approaches have been developed to
generate Cys oxidation ratios and measure protein expression
in the same experiment. In a differential alkylation approach,
peptides containing Cys (either chemically alkylated or initially
oxidized) are used to estimate Cys oxidation levels, while
peptides not containing Cys are used for measurement of protein
expression. Likewise, in cysTMTRAQ, differential isotope tagging
of Cys-containing and peptides that do not contain Cys allow
for measurement of both Cys oxidation and protein expression.
Therefore, if access toMS instrument time is limited, choosing an
approach that generates oxidation and protein expression data is
worth considering (Figure 9).
Biotin Switch Technique (BST)
The BST technique exploits the specificity and strong binding
affinity of biotin with avidin resin to enrich biotinylated Cys-
containing peptides from complex samples. Many approaches
such as iodoTMT, CysTMTRAQ, QTRP, TOP-ABPP use BST to
enrich Cys-containing peptides/proteins. This is an important
step in these approaches to enhance the abundance and coverage
of Oxi-Cys in biological samples. BST is widely used as a robust
technique to enrich Cys; however, non-specific interactions
might also occur if wash steps are not sufficiently stringent and
bound peptides/proteins are challenging to elute if cleavable
biotin is not used. In addition, the size of the biotin tags
could also prevent appropriate interactions with the Cys residue
(Gu and Robinson, 2016b).
Jaffrey et al. (2001) used BST to investigate S-nitrosylated
proteins. All Cys-containing free thiols are alkylated withMMTS,
while nitrosothiols are selectively reduced with ascorbate to form
free thiols, which are then blocked with thiol-modifying reagent
biotin–HPDP (N-[6-(biotinamido) hexyl]-3′-(2′-pyridyldithio)
propionamide). The biotinylated proteins are then purified
using streptavidin-agarose resin and selectively eluted with 2-
mercaptoethanol (2-ME) to break the disulphide linkage in
biotin-HPDP. However, cysteine residues modified by MMTS
and endogenous disulphides are also reduced to form free thiol
during this elution step (Jaffrey et al., 2001). Therefore, other
alkylating reagents such as IAM or NEM should be used to
alkylate Cys irreversibly to avoid this problem. Proteins are
separated on a Sodium dodecyl sulfate –polyacrylamide-gel
electrophoresis (SDS–PAGE), selected bands are then subjected
to tryptic digestion and MS analysis for identification of S-NO
PTMs (Jaffrey et al., 2001).
Another BST-based approach, SNOTRAP (S-NO trapping
by triaryl phosphine) was developed to selectively target
S-nitrosylated proteins to reveal those involved in the early
stages of neurodegeneration in a mouse model of Alzheimer’s
disease (Seneviratne et al., 2016). All initially reduced Cys are
blocked with IAM while S-nitrosylated proteins are directly
reacted with a biotin-SNOTRAP (b-SNOTRAP) probe to yield an
azaylide intermediate to form the disulfide–iminophosphorane
compound, which then is subject to reduction by TCEP before
blocking with NEM (Seneviratne et al., 2016). The biotin-
based enrichment of S-NO is performed at either protein
or peptide levels.
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Thiol-Affinity Resin-Assisted Capture
(RAC)
The enrichment of Cys-containing peptides/proteins based
on thiol-affinity RAC has been widely used in quantitative
proteomics analysis of reversible Oxi-Cys. Coupled with different
quantitative proteomics approaches (e.g., isotopic labeling,
isobaric tags, and LFQ), thiol-affinity resin has been used for the
purification of various kinds of selected Oxi-Cys PTMs, including
S-NO [SNO-RAC coupled with iTRAQ (Forrester et al., 2009),
OxcyscPILOT/SNO-RAC coupled with TMT (Gu and Robinson,
2016a), S-SG (Guo et al., 2014), and global Oxi-Cys PTMs RAC
coupled with LFQ (Paulech et al., 2013)]. The most popular RAC
is Thiopropyl sepharose R© 6B resin that consists of a chemically
stable ether linkage formed by an interaction between a reactive
2-thiopyridyl disulfide group with sepharose (Supplementary
Figure 2). RAC is used for the enrichment of Cys-containing
peptides through the formation of a covalent disulfide bond
between the Cys and the thiopropyl group of the resin. Non-
Cys-containing peptides are washed away by washing buffer (see
Guo et al., 2014 for details), and Cys-containing peptides are
eluted using a reducing reagent (DTT). Eluted peptides can be
directly analyzed by LC-MS/MS with label-free quantification or
can be labeled with either stable isotopic labeling or isobaric tags
if higher quantitative accuracy is required.
QUANTITATIVE MS-BASED
APPROACHES FOR ANALYSIS OF
OXI-CYS PTMs
There are two main types of data acquisition strategies, data-
dependent acquisition (DDA) and data-independent acquisition
(DIA). In DDA mode, a fixed number (Top N approach) of
peptides are selected based on their intensity in MS1 scans, for
fragmentation in MS2 scans. MS1 (intact peptide mass) and
MS2 (fragment ion masses) data are analyzed using database-
searching algorithms to score peptide-spectral matches (PSMs)
for peptide/protein identification. Peptides are usually quantified
using either MS1 or MS2 data, and well-established statistical
and bioinformatics strategies are used to identify significantly
different levels of peptides/proteins between conditions.
Many approaches use DDA for Oxi-Cys analysis, such as
differential alkylation, iodoTMT, SICyCLIA etc., but missing
values across multiplex/multiple samples is an issue that can
affect the statistical analysis of quantitative data. To overcome
this, an unbiased technology in quantitative proteomics – DIA,
such as sequential window acquisition of all theoretical mass
spectra (SWATH-MS) and targeted DIA (SRM/MRM), can be
used (Gillet et al., 2012). In a typical DIA analysis, a relatively
wide mass/charge window is used for the isolation of peptides for
fragmentation. In doing so, all detectible peptides are fragmented
and quantified, which results in improved accuracy and precision
of quantitation at the protein level with fewer missing values. The
complexity of MS2 data in DIA, however, results in a challenge
for data analysis, as it requires more sophisticated computation
compared to DDA to identify peptides from spectra generated
by the fragmentation of several peptides in a single MS2 scan.
Approaches, where specific proteins/peptide are targeted for
analysis (SRM/MRM and PRM) are also widely used for a robust
quantitation of selected peptides/proteins and their PTMs.
Label-Free Quantification (LFQ)
The development of advanced MS instrumentation (with
high mass accuracy, resolution and sensitivity), together
with highly reproducible nanoflow chromatography, has
allowed the widespread use of LFQ-based quantification in
bottom-up proteomics. LFQ can be used instead of labeling
approaches (stable isotopic labeling or isobaric tags) to quantify
proteins/peptides using sequential LC-MS/MS analysis of
samples. Compared to labeling approaches, LFQ offers a
higher dynamic range than isotope labeling methods, but the
quantitative accuracy is lower, and typically, more replicates
are required for robust quantitation. In this approach, each
digested proteome is run separately on an LC-MS/MS platform,
and the quantitation is carried out based on XIC (extracted
ion chromatogram) intensities (Wang et al., 2008). In XIC, the
ion current signal (in MS1) associated with each individual
peptide is used to reconstruct the area under the curve during
chromatography which is proportional to the amount of peptide
present. The performance of LFQ-based quantification can
be improved by the incorporation of more advanced data
processing. For example, retention time alignment across
samples and “matching between runs” in which missing values
are reduced by transferring peptide identifications based on
narrow mass and retention time windows. This minimizes
missing values due to poor fragmentation data or cases where
a peptide is not selected for fragmentation because it was
present at a lower amount in one sample compared to others
in an experiment.
Stable-Isotope Dimethyl Labeling
Stable-isotope dimethyl labeling employs different isotopomers
of formaldehyde and cyanoborohydride to introduce dimethyl
groups to the N-termini and side chains of lysine residues
which differ by at least 4 Da. This is used to label usually 2–3
samples, but up to 5 samples (5-plex) can be labeled and pooled
in a single experiment if other formaldehyde/cyanoborohydride
isotopomers are used (Wu et al., 2014). The application of
multiplexing for labeling multiple samples in a single experiment
offers many benefits as analysis of multiple samples can
be performed in the same experiment and thereby reduced
the amount of instrument time required. On the one hand,
given that samples are pooled and analyzed within an LC-
MS/MS acquisition, this type of quantification is more accurate
than sequential label-free quantification approaches. However,
because the samples are pooled, the peptide complexity is
increased, and up-front peptide fractionation may be required
depending on the initial sample complexity and acquisition speed
of the MS instrument.
Multiplex Isobaric Tagging
Multiplex approaches (iodoTMT and cysTMTRAQ) allow the
analysis of up to six different samples in a single experiment.
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This is achieved by labeling samples with chemical tags which
add the same overall mass to each peptide (same mass addition
in MS1), but when labeled peptides are fragmented in MS2 scans,
they generate signature (barcoded) ions used for quantitation
of each individual sample. The key difference between isobaric
tags and isotopic labeling approaches is that all isobaric tags
are identical in total mass (see Figure 4C). In contrast, isotopic
labeling masses are different when labeling peptides and peptides
are distinguished by a mass difference in MS1 scans. The
quantitation of peptides using isotopic labeling is performed
based on the intensity of peptides measured in MS1 spectra,
while that of the isobaric tagging approach is carried out based
on the intensity of tags cleaved from labeled peptides in MS2
spectra with signature masses (e.g., 126, 127, 128, 129, 130, and
131 m/z). In a complex digested sample, co-elution (from online-
HPLC) and co-isolation (at MS1) of peptides with others with a
similar m/z result can result in a combination of the reporter ion
intensity from different peptides, resulting in a bias in the relative
ratio of a peptide from different proteomes. This is a particular
challenge for quantifying low abundance peptides/proteins as the
interference is much higher. Specific data acquisition strategies
and statistical analysis packages have been developed to address
this issue of ratio compression (Pappireddi et al., 2019).
Multiple Reaction Monitoring (MRM)
MRM (also known as SRM, Selected Reaction Monitoring)
is used to analyze specific proteins/peptides of interest in a
complex sample by selectively targeting peptides to enhance
the reproducibility and accuracy of quantitation, especially
for low abundance proteins/peptides. This approach involves
the isolation of targeted peptides (enzymatically digested from
proteins of interest) and specific fragment ions from the targeted
peptides. This is typically performed in a triple quadrupole mass
spectrometer. The first and third quadrupoles are used as filters
to specifically select the targeted ions (m/z) corresponding to
peptides of interest and specific fragment ions fragmented from
the targeted peptides. The second quadrupole acts as a collision
cell for fragmentation of the targeted ions. The transition of
ion pairs (precursors/fragment ions) are monitored continuously
during the MS run to generate a spectrum that contains signal
intensities of specific transitions as a function of time (Lange
et al., 2008). Given that this approach uses a selective ion
pair technique, not a “full scan” technique like others, it can
improve sensitivity by up to two orders of magnitude and
the linear response over a wide dynamic range up to five
orders of magnitude compared to “full scan” technique (Lange
et al., 2008). MRM can measure peptides from more than 100
proteins per acquisition using high-speed triple quadrupole MS
in line with accurate retention time scheduling (Percy et al.,
2014). A variant of this approach, Parallel-reaction monitoring
(PRM), can be performed using a high-resolution instrument
such as the Orbitrap instrument. Unlike MRM in which typically
three fragment ions are monitored in transitions, in PRM all
fragment ions are measured for the set of targeted peptides
(Meyer and Schilling, 2017).
An approach named OxiMRM has been developed for
targeted Oxi-Cys proteomics analysis. It utilizes a stable isotopic
approach to label Cys residues via two different alkylating steps,
light (d0) and heavy (d5) stable isotope labeled NEM to label
reduced and Oxi-Cys, respectively (Figure 4B). These labeled
proteins are then subjected to immunoaffinity purification to
enrich a specific protein of interest before being digested with
trypsin and quantified using a multiple reaction monitoring
(MRM) method (Held et al., 2010). This technique offers a
highly sensitive and reproducible approach to target specific Cys
residues in proteins of interest that can be used to quantify both
sulfinic and sulfonic acid oxidation levels (Held et al., 2010).
Another method in this category, UPLC-pSRM (combination of
nano-UPLC and pseudo-SRM performed on a LTQ-Orbitrap),
has been introduced to detect and quantify irreversible Cys
oxidation (Lee et al., 2013) without any enrichment step. The
approach employs a high chromatographic resolution (using a
long reverse-phase nano-UPLC column) to separate different
forms of Oxi-Cys and a high mass accuracy, resolution and
sensitivity of an Orbitrap instrument for identification and
quantitation of modified Cys sites (Lee et al., 2013). The benefit
of this technique is that it allows direct detection of irreversibly
linked Oxi-Cys residues in peptides/proteins.
Cysteine-Specific Data Independent
Analysis (Cys-DIA)
The ultimate benefit of DIA is that it can measure most
detectible peptides falling in a selected m/z window to improve
the accuracy and precision of peptide quantitation with
minimal missing values. In that context, Cys-DIA was used
to analyze Cys-containing peptides purified with Thiopropyl
SepharoseTM 6B beads (as discussed in section “Thiol-affinity
resin-assisted capture”) to increase Cys-proteome coverage up
to 35% compared to conventional DIA/SWATH approach. In
brief, all reversible Oxi-Cys residues are reduced by (DTT
or TECP), and all free reduced Cys residues (newly formed
and native reduced Cys) are subjected to Cys purification.
These purified Cys-peptides are then analyzed on an Orbitrap
instrument (Q-Exactive HF-X) operated in high-resolution MS1
DIA mode (HRMS1-DIA) to quantify Cys-containing peptides
(Tahir et al., 2020). A typical selection of 25–50 m/z windows
covering from 400 to 1500 m/z is used, and all ionized peptides
within that range are fragmented, generating complex spectra of
fragmented ions. Unlike DDA data, DIA data can be searched
against a peptide spectral reference library generated from
separate DDA experiments to identify and quantitate peptides
(Tahir et al., 2020).
CYSTEINE OXIDATION IN
NEURODEGENERATIVE DISEASES
We have surveyed published articles using PubMed1, from the
last 20 years, for studies that include proteomic analysis of Cys
oxidation in neurodegenerative diseases with different keywords,
as shown in Figure S1. Keywords for searching included: proteo∗
and oxida∗ and cysteine (used as fixed keywords), and then other
1https://pubmed.ncbi.nlm.nih.gov/
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variables such as neuro∗, human, AD, Parkinson disease (PD),
multiple sclerosis (MS), and motor neuron disease (MND)/ALS.
Generally, Oxy-Cys studies have steadily increased over the last
two decades. However, when specific neurodegenerative disease
keywords (AD, PD, MS, MND, and ALS) were included, the
number of proteomics studies of Cys oxidation in the context of
neurodegenerative disease is strikingly low.Many hits were found
for PD and AD, but when these hits were manually inspected,
the total number of studies for Oxi-Cys proteomics was less than
ten; especially a combination of fixed keywords with human and
MND (or ALS) resulted in no hits.
Moreover, we have also examined data from the CSF
(cerebrospinal fluid) Proteome Resource2 containing 128 human
CSF proteomics datasets (4,192 proteins) available from 31
research articles for neurodegenerative disease studies (AD, MS,
PD, and ALS) from 2010 to 2019 (Guldbrandsen et al., 2017),
there were no Oxy-Cys proteomic studies. This indicates that
despite the oxidative state of Cys playing important roles in
neurodegenerative diseases, very little (or no) studies have been
performed to investigate how global changes in Cys oxidation
are altered in neurodegenerative diseases or how it changes in
response to disease progression and treatment. Here, we review
recent Oxi-Cys PTMs studies to characterize oxidation changes
in neurodegenerative diseases.
Alzheimer’s Disease
S-NO is implicated in AD through its association with impaired
metabolism, mitochondrial dysfunction, neuronal loss, and
protein misfolding and aggregation (Dyer et al., 2017). Various
methods have been used to measure changes in S-NO in mouse
models of AD and clinical samples. Using the OxcyscPILOT
approach, Dyer et al. (2017) identified 135 S-NO modified
proteins, of which 11 proteins were differentially regulated in an
AD (APP/PS1) mouse model. This approach allows comparison
of S-NO levels across different samples (up to 6 samples) as well
as measuring total (reduced and reversibly oxidized) cysteine-
containing peptides so that the levels of S-NO can be easily
normalized in a single experiment (Dyer et al., 2017). However,
this technique has not yet been applied to the analysis of
clinical samples.
Synaptic loss and neuroinflammation contribute to early
pathophysiological changes in AD. The induction of nitric
oxide synthase type 2 leads to increased nitric oxide levels and
S-NO of cysteine residues (Paula et al., 2010). An isobaric tag
approach, iodoTMT, was used to reveal the S-NO sites on Cys
residues of NOS2-dependent S-NO of synaptic proteins in mild
cognitive impairment (MCI) and AD and human control brain
tissues (Wijasa et al., 2020). Of 291 and 295 S-NO proteins
identified in synaptosome fractions, 16 and 9 S-NO proteins were
significantly increased in AD vs. MCI brains and AD vs. Ctrl,
respectively (Wijasa et al., 2020). Of these up-regulated S-NO
proteins, three proteins, myelin-oligodendrocyte glycoprotein
(MOG), glutathione s-transferase Mu 3 (GSTM3), and four and
a half LIM domains protein 1 (FHL1), were found at a higher
level in AD compared to either MCI or Ctrl cases (Wijasa
2https://proteomics.uib.no/csf-pr/
et al., 2020). Furthermore, this study identified 23 potential
S-NO biomarkers (see Wijasa et al., 2020 for details). The up-
regulation of MOG was associated with an increased production
of autoantibodies against MOG protein in AD, indicating early
demyelination of the hippocampal region (Papuć et al., 2015).
The exact functions of FHL1 or GSTM3 in synapses are still
unclear (Wijasa et al., 2020). Other S-NO modified proteins
such as neurocan core protein (NCAN), calmodulin-dependent
protein kinase type II subunit gamma (CAMK2G), CD44 and
aspartate aminotransferase (GOT1) were also reported to be
increased in abundance in AD brains as well as in human
CSF (Wijasa et al., 2020), representing potential AD biomarkers
for future study.
Antibodies to measure specific Cys oxidation types have been
used for the detection and measurement of protein oxidation
in neurodegenerative diseases, e.g., S-nitrosocysteine antibody
for S-NO. In an early Oxi-Cys proteomics study, Choi et al.
(2004) applied a 2-D protein gel-based approach coupled with
immunostaining and MS analysis to discover three human
brain UCH-L1 isoforms that contain Oxi-Cys, suggesting the
oxidation might damage the ubiquitination/de-ubiquitination
machinery involved in the etiology of AD and PD. Newman
et al. (2007) utilized 2-D-Oxyblots and MS analysis to identify
specific targets of S-glutathionylated Cys in AD inferior
parietal lobule (IPL) compared to control IPL, in which three
proteins, deoxyhemoglobin, α-crystallin B, glyceraldehyde
phosphate dehydrogenase (GAPDH), and α-enolase, were
significantly S-glutathionylated in AD IPL (Newman et al.,
2007). The exact functions of these S-glutathionylated proteins
were not elucidated, but the study identified several proteins
sensitive to oxidative stress in the AD brain (Newman et al.,
2007). Using a similar approach, Zahid et al. (2014) reported
three proteins [voltage-dependent anion-selective channel
protein 2 (VDAC2), superoxide dismutase [Mn] (SOD2),
and fructose-bisphosphate aldolase C (ALDOC)] that were
S-glutathionylated in autopsied brain specimens (hippocampus,
substantia nigra and cortex) (Zahid et al., 2014). Although
MS was used to identify S-glutathionylated proteins, the
exact location of Oxi-Cys sites within these proteins was only
predicted by in silico analysis. The altered levels of S-NO
in AD might contribute to disease-related consequences
(Zahid et al., 2014).
Transthyretin (TTR), an abundant CSF protein, contains
both free and oxidized Cys residues. The relative changes
between these two states generate different TTR isoforms under
oxidative stress conditions (Poulsen et al., 2014). This protein can
bind to beta-amyloid peptide, and familial amyloidosis diseases
(e.g., familial amyloid polyneuropathy) have been associated
with its variants (Biroccio et al., 2006). In a later study,
Poulsen et al. (2014) adopted this approach to characterize
the oxidation isoforms of TTR in CSF from AD, MCI, and
normal pressure hydrocephalus (NPH) patients and HCs, and
an increased oxidation level of Cys10 in TTR isoforms was
observed in AD and MCI compared to other groups. This
offers a potential novel biomarker for the diagnosis of AD in
patients but would need to be investigated in larger cohorts of
patients for validation.
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Multiple Sclerosis
Multiple sclerosis is a neuroinflammatory disease associated
with demyelination and axonal damage (Compston and Coles,
2002). Oxidative stress is a crucial factor contributing to
the disease pathology via demyelination and oligodendroglia
degeneration (Konat and Wiggins, 1985). Using a modified
proteomics approach, which excluding reduction and alkylation
steps to retain glutathione attached to cysteine through disulfide
linkage, coupled with a targeted database search, Srivastava
et al. (2019) characterized S-glutathionylation of CSF proteins
in MS. In particular, they identified several proteins that
were glutathionylated in patients with MS during a relapse,
including three proteins (ECSOD, A1AT, and PLTP) which were
oxidized at functionally important positions in their structure
(Srivastava et al., 2019). This indicates that S-glutathionylation
may negatively regulate the function of these proteins in MS
(Liedhegner et al., 2012). However, given that this study has a
limited sample size, validation of these oxidation changes needs
to be performed in larger patient cohorts to confirm a link
between S-glutathionylation and MS (Srivastava et al., 2019).
DISCUSSION AND FUTURE DIRECTIONS
Over the last 20 years, proteomic analysis of Cys oxidation
has revealed global profiles of the redox network in many
biological systems. Two main types of analyses have been
performed, oxidation site mapping and quantitation and thiol
reactivity profiling (Fu et al., 2020). The site mapping Oxi-Cys
strategy has many approaches (BST, RAC, iodoTMT, etc.) to
identify redox-sensitive cysteines in proteins and quantitation of
dynamic changes in cysteine oxidation in response to a variety of
perturbations (Jaffrey et al., 2001; Forrester et al., 2009; Guo et al.,
2014; Gu and Robinson, 2016a). A summary of approaches used
for the analysis of Cys PTMs and their applications is shown in
Figure 9, and further details of the advantages and disadvantages
of each method are listed in Supplementary Table 1.
Advantages and Disadvantages
The identification and quantitation of various forms of cysteine
oxidation remain challenging because of the low abundance
of cysteine in the proteome and the sub-stoichiometric nature
of oxidation. It requires robust tools to characterize the Oxi-
Cys proteome. As discussed above, many approaches, mostly
attempting to enrich Oxi-Cys residues or Cys-containing
peptides, have been established, such as iodoTMT, isoTOP-ABPP,
QTRP, and DiaAlk. Selective Oxi-Cys proteomics approaches,
mainly based on BST or probes, offer higher sensitivity, specificity
and precision (Mnatsakanyan et al., 2019) than methods that
don’t incorporate an enrichment step (differential alkylation,
SICyLIA, or CysTMTRAQ). However, Oxi-Cys approaches,
which rely on an enrichment step, might not directly capture the
native oxidized state of proteins under physiological conditions.
An alternative to this is the SICyLIA approach, a simple, unbiased
and robust method to sensitively detect and accurately quantify
global oxidized Cys-proteomes since it does not require Cys
enrichment (van der Reest et al., 2018). However, given the lack
of an enrichment step in the SICyLIA approach, it may be less
suitable for the analysis of low abundance proteins and cases
where the stoichiometry of oxidation is low.
Most of the approaches listed in Figure 9 (apart
from Differential alkylation and DiaAlk) require an extra
experiment/additional MS time to measure protein expression
levels which is necessary for the normalization of Cys oxidation
levels. This is an important consideration if protein expression
differences are likely to occur between experimental and
control conditions.
Most of the methods shown in Figure 9 are not directly
compatible with the analysis of irreversible cysteine oxidation.
However, in some cases, data from some approaches such as
differential alkylation or SICyLIA can allow the identification
of irreversible Cys oxidation (S-O3H or S-O2H) if these
modifications are selected in database searching algorithms. Click
chemistry-based approaches offer many benefits for the study of
reversible Oxi-Cys residues, such as high selectivity and direct
measurement and determination of exact sites of Cys containing
PTMs. However, there are no available probes designed for
targeting and purifying peptides/proteins containing irreversible
Oxi-Cys (S-O3H), but a few for S-O2H, such as the DiaAlk probe
have been developed (Figure 5B).
Isobaric tag-based approaches (iodoTMT and CysTMTRAQ)
have been used in several Oxy-Cys PTM studies, redox and
electrophile reactive Cys proteome applications (Gygi et al.,
1999; Jaffrey et al., 2001; Chouchani et al., 2017) because of the
commercial availability of reagents as well as their multiplexing
capability. However, the high cost of reagents and high-end MS
instrumentation required to avoid ratio compression due to co-
isolated peptides is potentially a barrier to the wide adoption of
these approaches. Furthermore, the large structure of isobaric
tag labeling reagents may have reduced accessibility to react with
sterically buried Cys in native conditions (Fu et al., 2020).
Perspectives
Recent advances in MS-based proteomics, biomarker discovery
in the context of neurodegenerative disease has significant
potential. Applications include the identification of biomarkers
for earlier diagnosis of disease and biomarkers of drug-target
engagement that can be used for the development and testing
of new therapies.
Recent studies using protein biomarkers for AD
diagnosis highlight the advances in biomarker discovery
for neurodegenerative diseases. The diagnosis of AD relies
on a combination of clinical criteria, brain scans and
a neurological exam. Disease pathology is reflected in
biomarkers, including amyloid-beta 1–42 peptide (Aβ1−42),
tau protein (t-tau), and tau phosphorylated at Thr-181 (p-
tau181) in CSF (Begcevic et al., 2018). However, only two
validated methods have been used to identify amyloid-beta
in the brain; measurement of levels in CSF or positron-
emission tomography (PET) brain imaging (Nakamura
et al., 2018). Nakamura et al. (2018) recently developed an
immunoprecipitation-MS (IP-MS) based assay to measure
amyloid-beta precursor protein (APP)669−711/amyloid-β
(Aβ)1−42 and Aβ1−40/Aβ1−42 ratios in plasma to predict
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brain amyloid-β burden. The performance of this composite
biomarker was high [areas under the receiver operating
characteristic curves (AUCs) in both data sets (discovery, 96.7%,
n = 121 and validation, 94.1%, n = 111)]. It had an accuracy of
90% compared to diagnosis with PET imaging, demonstrating
the potential clinical utility of this MS-based biomarker assay
(Nakamura et al., 2018).
Going beyond protein expression level biomarkers to
protein modification markers in neurodegenerative disease is
the next step toward accessing, for example, earlier markers
of disease progression and a means to evaluate therapeutic
efficacy. For example, the application of Oxi-Cys proteomics
approaches to study changes in oxidation in CSF from
patients in longitudinal studies may reveal proteins with an
oxidation status that correlates to disease progression. The
efficacy of therapeutics designed to reduce oxidative stress
in patients could be tested for their ability to reduce the
level of these oxidation biomarkers and would therefore
allow measurement of target engagement in clinical studies.
There is also a variety of preclinical applications of Oxi-
Cys proteomics in which the impact of specific human
disease mutations on oxidation profiles can be assessed
in animal models.
It is necessary to develop reliable proteomics approaches
to build a global resource of (reversibly and irreversibly)
Oxi-Cys proteomes in different clinical samples and types of
neurodegenerative diseases (brain tissues, CSF, blood serum,
etc.) that can be used to identify biomarkers in diagnosis
and drug development studies. This resource could focus on:
specific cell types of global Oxi-Cys proteomes to understand
the diseasemechanism of neurodegenerative diseases; integration
of Oxi-Cys proteomics networks in brain tissue, CSF or plasma.
Furthermore, these will also contribute to the understanding of
neurodegenerative disease pathogenesis, progression,monitoring
and treatment. Indeed, the integration of Oxi-proteomics data
and data from the metabolomics of oxidative stress combined
with in silico computational models, will provide a clearer picture
of oxidative stress processes in neurodegenerative diseases.
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